“…The most well-characterized ones include tocilizumab (Actemra, RoActemra; F. Hoffmann-La Roche Ltd., Basel, Switzerland), which is a humanized mAb targeting IL-6R, 45,46 and sarilumab (Kevzara ® ; Sanofi and Regeneron Pharmaceuticals, Inc., Paris, France), which is a human mAb targeting IL-6R. 47,48 The mAbs that block the activity of IL-6 itself include the human mAbs sirukumab, 49,50 the humanized mAbs clazakizumab and satralizumab (Enspryng ® ; F. Hoffmann-La Roche Ltd., Basel, Switzerland), 51 and the chimeric mAb siltuximab (Sylvant ® ; EUSA Pharma, Hemel Hempstead, UK). 52 This article focuses on the humanized mAb olokizumab, which binds to IL-6, developed by R-PHARM (Moscow, Russia) under the license agreement with UCB Pharma (Brussels, Belgium).…”